Neuroendokrine Tumorerkrankungen Immuntherapie. Ulrich Keilholz Charité Comprehensive Cancer Center
|
|
- Tabitha Hill
- 6 years ago
- Views:
Transcription
1 Neuroendokrine Tumorerkrankungen Immuntherapie Ulrich Keilholz Charité Comprehensive Cancer Center
2 effector cell Antigen TCR TCR Antigen Antigen presenting cell Tumor cell Apoptosis Chemotherapy Radiotherapy Necrosis
3 In all cancer patients, immune-surveillance has failed effector cell Antigen TCR TCR Antigen Antigen presenting cell Tumor cell Apoptosis Chemotherapy Radiotherapy Necrosis
4 Failure of Immunesurveillance T-cell T- cell Tumor Tumor Tumor Tumor no Antigen no AG-specific blockade of Immunoevasisve T cell response AG-specific Microenvironment T cells
5 Failure of Immunesurveillance T-cell T- cell Tumor Tumor Tumor Tumor no Antigen no AG-specific blockade of Immunoevasisve T cell response AG-specific Microenvironment T cells
6
7
8 Failure of Immunesurveillance T-cell T- cell Tumor Tumor Tumor Tumor no Antigen no AG-specific blockade of Immunoevasisve T cell response AG-specific Microenvironment T cells
9 effector cell Stimulation (e.g. Interleukin-2) Antigen TCR TCR Antigen Antigen presenting cell Tumor cell
10 DTIC, Cisplatin, IFNa with or without intravenous Interleukin-2 in advanced melanoma Study Coordinator: Ulrich Keilholz, Berlin Co-Coordinator: Alexander Eggermont, Rotterdam EORTC trial J Clin Oncol 2005
11 Overall Survival Logrank test: p= (years) O N Number of patients at risk : Arm A Arm B J Clin Oncol 2005
12 Failure of Immunesurveillance T-cell T- cell Tumor Tumor Tumor Tumor no Antigen no AG-specific blockade of Immunoevasisve T cell response AG-specific Microenvironment T cells
13 Vaccine effector cell TCR Antigen Antigen TCR TCR Antigen Antigen presenting cell Tumor cell
14
15 T-cell-Targets for immunoregulatory antibodies I Mellman et al. Nature 480, (2011)
16 effector cell CTLA4 CD28 PD1 B7 B7 PD-L1 Antigen presenting cell Tumor cell CTLA4 und PD1: Die zentralen Immune Checkpoints
17 Anti CTLA4 effector cell CTLA4 CD28 PD1 B7 B7 PD-L1 Antigen presenting cell Tumor cell anti-ctla4 erlaubt Entwicklung von AUTOIMMUNITÄT
18 effector cell Anti PD1/PDL1 CTLA4 CD28 PD1 B7 B7 PD-L1 Antigen presenting cell Tumor cell anti-pd1 erlaubt EXECUTION der IMMUNITÄT
19
20 Melanom
21 Melanom
22 RCC
23 NSCLC
24 Toxicity Grade CTLA-4 Blockade With Ipilimumab Kinetics of iraes in Melanoma Weber JS, et al. J Clin Oncol Time (weeks)
25 Approximate proportion of patients (%) PD-1 Blockade: Kinetics of iraes in Melanoma Time (weeks) Skin Gastrointestinal Endocrine Hepatic Pulmonary Renal Weber JS, et al. ASCO
26 Change From Baseline in Tumor Size, % Example: Pembrolizumab Antitumor Activity Melanoma 1 (N=655) KEYNOTE NSCLC 2 (N=262) KEYNOTE-001 H&N 3 (N=132) KEYNOTE-012 Urothelial 4 (N=33) KEYNOTE-012 Gastric 5 (N=39) KEYNOTE TNBC 6 (N=32) KEYNOTE-012 chl 7 (N=29) KEYNOTE-013 Mesothelioma 8 (N=25) KEYNOTE-028 Ovarian 9 (N=26) KEYNOTE-028 SCLC 10 (N=20) KEYNOTE-028 Esophageal 11 (N=23) KEYNOTE-028 chl = classical Hodgkin s lymphoma; H&N = head and neck; NSCLC = non-small cell lung cancer; TNBC = triple-negative breast cancer. 1. Daud A 26 et al ASCO; 2. Garon EB et al. ESMO 2014; 3. Seiwert T et al ASCO; 4. Plimack E et al ASCO; 5. Bang YJ et al ASCO; 6. Nanda R et al. SABCS 2014; 7. Moskowitz C et al ASH Annual Meeting; 8. Alley EA et al AACR; 9. Varga A et al ASCO; 10. Ott PA et al ASCO; 11. Doi T et al ASCO.
27 Change From Baseline in Tumor Size, % Example: Pembrolizumab Antitumor Activity Melanoma 1 (N=655) KEYNOTE NSCLC 2 (N=262) KEYNOTE-001 H&N 3 (N=132) KEYNOTE-012 Urothelial 4 (N=33) KEYNOTE-012 Gastric 5 (N=39) KEYNOTE TNBC 6 (N=32) KEYNOTE-012 chl 7 (N=29) KEYNOTE-013 Mesothelioma 8 (N=25) KEYNOTE-028 Ovarian 9 (N=26) KEYNOTE-028 SCLC 10 (N=20) KEYNOTE-028 Esophageal 11 (N=23) KEYNOTE-028 chl = classical Hodgkin s lymphoma; H&N = head and neck; NSCLC = non-small cell lung cancer; TNBC = triple-negative breast cancer. 1. Daud A 27 et al ASCO; 2. Garon EB et al. ESMO 2014; 3. Seiwert T et al ASCO; 4. Plimack E et al ASCO; 5. Bang YJ et al ASCO; 6. Nanda R et al. SABCS 2014; 7. Moskowitz C et al ASH Annual Meeting; 8. Alley EA et al AACR; 9. Varga A et al ASCO; 10. Ott PA et al ASCO; 11. Doi T et al ASCO.
28 PD-1 Blockade in Tumors with Mismatch Repair Deficiency Presented By Dung Le at 2015 ASCO Annual Meeting
29 Mutations per tumor Presented By Dung Le at 2015 ASCO Annual Meeting
30 Pembrolizumab (anti-pd1) 10 mg/kg alle 2 Wochen Slide 12 Presented By Dung Le at 2015 ASCO Annual Meeting
31 Slide 13 Presented By Dung Le at 2015 ASCO Annual Meeting
32 Slide 15 Presented By Dung Le at 2015 ASCO Annual Meeting
33 Slide 17 Presented By Dung Le at 2015 ASCO Annual Meeting
34 2WUY1M (BER-04) NET Single Nucleotide Variants (SNVs) 7987 Insertions/Deletions (Indels) Mutationslast des Tumors Signatur entspricht: C11 alkylating agents (nicht POL eta, da dominant C>T) PI3K-AKT-mTOR Developmental Pathways snv: 2 in NOTCH2, 3 in FBXW7 exp-: NOTCH1, HOXC11 Tyrosine Kinases snv: ERBB3 exp+: RET, ERBB4 exp-: STK11 Hypermutation 7987 nonsilent SNVs, viele nicht in RNA oder mit sehr geringer AF RAF-MEK-ERK snv: NRAS Cell Cycle DNA Damage Response snv: POLE germline rar + zweimal somatic, exp-, MSH2/6, FANCL, ERCC3 exp+: ERCC4/6 exp-: BAP1 Other snv: CDC73 exp+: PDCD1LG2, CD274, CTLA4, viele B- und T-Zell- Gene => Infiltration snv = single nucleotide variant, in = insertion, del = deletion, amp = amplification, exp+ = increased expression exp- = decreased expression, fus = fusion
35 Konsequenzen Immuntherapie mit Checkpoint-Inhibitoren öffnet komplett neue Perspektiven Saubere Diagnostik nötig, um Wirksamkeit einzuschätzen Einfach Dysfunktions-Mutationen Hohe Mutationslast Starke Inflammation Schwierig Treiber-Mutationen Niedrige Mutationslast Keine Inflammation
Merck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationMerck Oncology Overview ASCO 2017
Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking
More informationMerck Oncology Overview ASCO 2017
Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking
More informationLA QUARTA ARMA CONTRO IL CANCRO
LA QUARTA ARMA CONTRO IL CANCRO Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure Employment or
More informationMANAGEMENT OF IMMUNE-RELATED SIDE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS
MANAGEMENT OF IMMUNE-RELATED SIDE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS John B.A.G. Haanen MD PhD CONTENT OF THIS PRESENTATION General aspects of immune related adverse events related to immune checkpoint
More informationImmunotherapy Update in Metastatic Breast Cancer
ANZBCTG Annual Meeting 2017 Immunotherapy Update in Metastatic Breast Cancer Sherene Loi, MBBS (Hons), FRACP, PhD Peter MacCallum Cancer Centre, Melbourne, Australia EFFICACY OF CHECKPOINT BLOCKADE IN
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationImmunology and Immunotherapy. Ulrich Keilholz Charité Comprehensive Cancer Center
Immunology and Immunotherapy Ulrich Keilholz Charité Comprehensive Cancer Center DISCLOSURE SLIDE Advisory boards, speaker bureau, trial support, research collaboration Amgen AstraZeneca BMS Boehringer
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationPursuing Precision in Immuno-Oncology Biology, Big data and Biomarkers
Pursuing Precision in Immuno-Oncology Biology, Big data and Biomarkers Tom Lillie, MD, PhD Vice President, EU clinical development MSD Change From Baseline in Tumor Size, % Pembrolizumab monotherapy has
More informationEarly Development of Immuno-oncology Drugs Novel Targets, Technology Platforms, and Trial Designs
Early Development of Immuno-oncology Drugs Novel Targets, Technology Platforms, and Trial Designs The 4th International Conference on Phase 1 and Early Phase Clinical Trials Archie Tse MD PhD Oncology
More informationRecent Updates in Cancer Immunotherapy
Recent Updates in Cancer Immunotherapy H. Miles Prince Epworth Healthcare Peter MacCallum Cancer Centre How do we choose? What is the next new flavour? Where does immunotherapy fit in? St Sebastian Archilles
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationNew kids on the block: Immunotherapy in melanoma and GI Malignancies. Ralph P.W. Wong, MD FRCPC
New kids on the block: Immunotherapy in melanoma and GI Malignancies Ralph P.W. Wong, MD FRCPC "Cry 'Havoc!', and let slip the dogs of war Julius Caesar Act iii. Sc. 1 UPCON Primary Care Conference Ralph
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY
ENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY Lauren Clarine DO, Renil Rodriguez Martinez MD, Matthew Levine MD, Amy Chang MD, and Megan McGarvey MD May 6, 2017 Immune checkpoint inhibitors
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationImmunotherapie: algemene principes
Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationIMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA
IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess
More informationHistology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
More informationSpecial Situation: Brain metastases
ESMO Advanced Course on Unsolved Questions in Immuno-Oncology February 16-17 2018, Amsterdam, Netherlands Special Situation: Brain metastases Matthias Preusser, MD Associate Professor of Medicine Department
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationKombination von Checkpointinhibitoren beim malignen Melanom
Kombination von Checkpointinhibitoren beim malignen Melanom Dirk Jäger Medizinische Onkologie Nationales Centrum für Tumorerkrankungen Universitätsklinikum Heidelberg Ipilimumab beim metastasierten Melanom
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationCANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center
CANCER IMMUNOTHERAPY 2018 Presented by John A Keech Jr DO MultiCare Regional Cancer Center Successful anti-cancer immunity is autoimmunity Green, The Scientist, 2014 Immunotherapy strategies Cancer vaccines
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationImmunotherapy & radiotherapy
Immunotherapy & radiotherapy Eric Deutsch MD PhD Gustave Roussy Cancer Campus Image courtesy of Gustave Roussy Institute Disclosure & Disclaimer An honorarium is provided by Accuray for this presentation
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationHighlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationNew experimental targets for gastric cancer Andrés Cervantes
New experimental targets for gastric cancer Andrés Cervantes Professor of Medicine Outline Acquired capabilities of Cancer IGFR pathway PI3K-AKT-m-TOR pathway MET pathway FGFR pathway Check point inhibitors
More informationToxicity from Checkpoint Inhibitors. James Larkin FRCP PhD
Toxicity from Checkpoint Inhibitors James Larkin FRCP PhD Disclosures Research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): BMS, Eisai, GSK, MSD, Novartis, Pfizer, Roche/Genentech
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationOptimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma
Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,
More informationCurrent practice, needs and future directions in immuno-oncology research testing
Current practice, needs and future directions in immuno-oncology research testing Jose Carlos Machado IPATIMUP - Porto, Portugal ESMO 2017- THERMO FISHER SCIENTIFIC SYMPOSIUM Immune Therapies are Revolutionizing
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationState of the Art in Development of Immunotherapy. Alex A. Adjei. ESMO AFRICA Cape Town February 15, MFMER slide-1
State of the Art in Development of Immunotherapy Alex A. Adjei ESMO AFRICA Cape Town February 15, 2018 2016 MFMER slide-1 DISCLOSURE OF INTEREST Alex A. Adjei Institutional financial interests : Clinical
More informationHaemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist
Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Development and clinical experience Monique Minnema, hematologist Consultancy for disclosures Amgen, Celgene, Jansen Cilag, BMS, Takeda Immune
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationCancer Immunotherapy: an Emerging Paradigm
Cancer Immunotherapy: an Emerging Paradigm Branimir I. Sikic, MD Professor of Medicine Stanford University Nevada Cancer Control Summit Reno, November 6, 217 T-Cell Response: Second Signals to Accelerate
More informationLicia Rivoltini, MD Unit of Immunotherapy of Human Tumors
Licia Rivoltini, MD Unit of Immunotherapy of Human Tumors The complex network of anti-tumor immunity Innate immunity First line defense Tumor cell Adaptive immunity Specificity & memory Kidd et al., Nature
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationRare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham
Rare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham Classifying melanoma Melanoma (site of origin, thickness,
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationInmunoterapia en tumores digestivos no colorrectales
Inmunoterapia en tumores digestivos no colorrectales Santander, 13 de Julio del 2017 Maria Alsina, MD PhD Hospital Universitari Vall d Hebron Outline Introduction Hepatocarcinoma Pancreatic Cancer Gastric
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationDisclosure Information. Mary L. Disis
Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationAdvances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016
Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationFuture Directions in Immunotherapy
Future Directions in Immunotherapy Naiyer Rizvi, MD Price Chair, Clinical Translational Medicine Director of Thoracic Oncology Director of Immuno-Oncology Columbia University Medical Center New York, New
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationImmune checkpoint inhibition in melanoma. John Haanen
Immune checkpoint inhibition in melanoma John Haanen ESMO Preceptorship Singapore 217 Immune Checkpoint inhibitors Immune checkpoints play an important role in immune tolerance Cancer hijacks many of these
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationBasic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA
Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)
Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationImmunotherapy for Breast Cancer Clinical Development
Immunotherapy for Breast Cancer Clinical Development Laurence Buisseret, MD, PhD Breast Cancer Translational Research Laboratory Institut Jules Bordet Université Libre de Bruxelles (ULB) ESMO preceptorship
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationHarnessing the immune system to combat cancer. Gary Middleton, University of Birmingham
Harnessing the immune system to combat cancer Gary Middleton, University of Birmingham Going nowhere fast Vansteenkiste J et al. Lancet Oncol. 2016 Apr 27. pii: S1470-2045(16)00099-1. Immune checkpoints
More informationNivolumab in Hodgkin Lymphoma
Nivolumab in Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Chair, Lymphoma Group Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers Squibb Celldex Therapeutics Seattle
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationHARNESS THE POWER OF THE IMMUNE SYSTEM TO FIGHT CANCER
OncoPept TM HARNESS THE POWER OF THE IMMUNE SYSTEM TO FIGHT CANCER OncoPept identifies and delivers priortized T-cell neo-epitopes from the patient's tumor mutanome 2 What is OncoPept? OncoPept is an integrated
More information2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los
More informationImmunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Lawrence G. Lum, MD, DSc Karmanos Cancer Institute and Wayne State University Advances in Cancer Immunotherapy
More information